With approval in sight, Vifor expands deal for partner's anti-itch drug

Cara Therapeutics struck a licensing deal with Vifor Pharma that may be worth as much as $440 million as the biotech prepares to seek approval of its anti-itch medicine for dialysis patients with chronic kidney disease-associated pruritus (CKD-aP).